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Abstract 
Ketone bodies are crucial energy substrates during states of low carbohydrate availability. 
However, an aberrant regulation of ketone body homeostasis can lead to complications such 
as diabetic ketoacidosis. Exercise and diabetes affect systemic ketone body homeostasis, but 
the regulation of ketone body metabolism is still enigmatic. Using mice with either a 
knockout or overexpression of the peroxisome proliferator-activated receptor γ coactivator 1α 
(PGC-1α) in skeletal muscle, we show that PGC-1α regulates ketolytic gene transcription in 
muscle. Furthermore, ketone body homeostasis of these mice was investigated during fasting, 
exercise, ketogenic diet feeding and after streptozotocin injection. In response to these 
ketogenic stimuli, we show that modulation of PGC-1α levels in muscle affects systemic 
ketone body homeostasis. Moreover, our data demonstrate that skeletal muscle PGC-1α is 
necessary for the enhanced ketolytic capacity in response to exercise training and 
overexpression of PGC-1α in muscle enhances systemic ketolytic capacity and is sufficient to 
ameliorate diabetic hyperketonemia in mice. Using cultured myotubes, we also show that the 
transcription factor estrogen related receptor α (ERRα) is a partner of PGC-1α in the 
regulation of ketolytic gene transcription. Collectively, these results demonstrate a central role 
of skeletal muscle PGC-1α in the transcriptional regulation of systemic ketolytic capacity. 
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Introduction 
During prolonged starvation, when carbohydrate availability is low, the ketone bodies (KB) β-
hydroxybutyrate (βOHB) and acetoacetate (AcAc) are important metabolic fuels to help 
maintain energy homeostasis (1). KBs are produced in the liver and subsequently metabolized 
to acetyl-CoA in extra-hepatic organs. The majority of KB metabolism occurs in the 
mitochondria and is catalyzed by the enzymes 3-hydroxybutyrate dehydrogenase, type 1 
(BDH1), succinyl-CoA:3-ketoacid-coenzyme A transferase 1 (OXCT1) and acetyl-CoA 
acetyltransferase 1 (ACAT1) (2). Mutations of genes encoding these enzymes are associated 
with exacerbated ketosis in humans (3). Moreover, knockout of the rate-limiting ketolytic 
enzyme OXCT1 leads to severe hyperketonemia and lethality in mice (4). Hyperketonemia is 
a common complication in diabetic patients, which can lead to severe and possibly lethal 
ketoacidosis (5), and has in part been attributed to impaired peripheral KB oxidation (6). 
However, relatively little is known about the transcriptional regulation of ketolytic enzymes 
(7). The peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) is an 
important transcriptional coactivator, and has a well-established role in the regulation of 
mitochondrial metabolic processes such as oxidative phosphorylation and TCA cycle (8). 
While these metabolic pathways are important for complete oxidation of KBs, it is not known 
whether PGC-1α can directly affect expression of ketolytic genes in skeletal muscle. Here, we 
demonstrate that PGC-1α is a transcriptional regulator of ketolytic enzymes and KB 
transporters in skeletal muscle. Moreover, we show that modulation of ketolytic gene 
transcription in skeletal muscle by PGC-1α affects systemic ketosis in response to various 
stimuli, such as fasting, low-carbohydrate diet feeding and exercise. In line with this, muscle-
specific overexpression of PGC-1α can reduce hyperketonemia in both healthy and diabetic 
mice, and PGC-1α thus constitutes a novel therapeutic target to protect against 
hyperketonemia and diabetic ketoacidosis. 
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Materials and Methods 
Mice and diets - Animals were housed in a facility with 12-h light/12-h dark cycle with free 
access to food and water. Experiments were performed in accordance with federal guidelines 
and were approved by the Kantonales Veterinäramt of Kanton Basel-Stadt. PGC-1α muscle-
specific transgenic mice (mTG) and global PGC-1α-knockout mice (gKO) are described 
elsewhere (9, 10). The PGC-1α muscle-specific knockout mice (mKO) used in this study 
differ from previous publications (11), and were generated by crossing PGC-1αloxP/loxP mice 
(10) with HSA-Cre transgenic mice. Mice used were males, aged between 10 – 14 weeks, 
unless otherwise noted. Chow diet (AIN-93G; 7% fat, 58.5% carb. and 18% protein) and 
ketogenic diet (XL75:XP10; 74.4% fat, 3% carb. and 9.9% protein) were provided by Provimi 
Kliba AG, Kaiseraugst, Switzerland. 
Fasting and cold exposure – Mice were fasted for 24 hours with free access to water. For 
cold-exposure, cages without bedding were pre-cooled at 4°C overnight. Mice were 
transferred to these cages at 4°C for 8 hours without access to food. 
βOHB tolerance test - Mice were fasted for 5 hours in the morning, and then received a 
bolus intraperitoneal (I.P.) injection of 1.5 g/kg bodyweight Na-βOHB (Sigma). Blood βOHB 
levels were measured in tail vein blood at 0, 15, 30, 45, 60 and 90 minutes after injection. 
Streptozotocin – Male mice, aged 20-24 weeks, were fasted for 10 hours and subsequently 
injected with either citrate buffer (CB) or Streptozotocin (STZ) (Sigma) in CB, I.P. at a dose 
of 150 mg/kg. 10% sucrose was administered to the drinking water of the mice during the first 
24 hours after injection. 
Acute and chronic exercise - Exercise training was performed by giving mice free access to 
running wheels (Columbus instruments) in their home cages for 8 weeks, starting from the 
age of 10-12 weeks.  Sedentary control groups were housed in cages without running wheels.  
Mice were removed from their running wheel cages 24 hours prior to either βOHB tolerance 
test or sacrifice. For post-exercise ketosis tests, animals were acclimatized to treadmill 
running 2 days before the start of the experiment, for 5 minutes at 8 meters/minute (m/m) 
followed by 5 minutes at 10 m/m, at an incline of 5°. For the actual experiment, treadmill 
(Columbus instruments) was kept at an incline of 5°. The program started at 5 m/m for 5 
minutes, followed by 8 m/m for 10 minutes.  The speed of the treadmill was then increased by 
2 m/m every 15 minutes. Basal blood βOHB was assessed in tail-vein blood pre-exercise.  
Mice were removed from the treadmill after 80 minutes of running, before any of the mice 
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reached terminal exhaustion.  Blood βOHB levels were measured in tail vein blood at 0, 30 
and 180 minutes post-exercise. 
Blood analysis - Blood glucose and βOHB were measured in a tail vein blood using a 
handheld glucose meter (Accu-Chek, Roche) or βOHB-meter (Precision Xtra, Abbott). For 
plasma analysis, whole tail-vein blood was collected in Microvette tubes (Sarstedt). Plasma 
analysis was performed using colorimetric tests according to the manufacturers’ instructions; 
non-esterified fatty acids (HR Series NEFA-HR(2); Wako Diagnostics), acetoacetate 
(Acetoacetate Assay Kit; Abcam) and insulin (Ultra-sensitive mouse insulin ELISA kit, 
Crystal Chem Inc). 
RNA extraction and qRT-PCR – All tissue samples for RNA extraction were collected 
between Zeitgeber (ZT) 2-5. For basal measurements, mice were fasted for 2 hours before 
tissue samples were collected. For fasting experiments, mice were fasted for 24 hours before 
tissue samples were collected. Frozen tissue or cells were homogenized and total RNA was 
extracted using TRIzol reagent (Invitrogen). cDNA synthesis was performed using 1 µg of 
total RNA. Semi-quantitative Real-time PCR analysis was performed using Fast SYBR Green 
master mix (Applied Biosystems) on a StepOnePlus Real-Time PCR System (Applied 
Biosystems). Relative expression levels for each gene of interest were calculated with the 
ΔΔCt method, using either 18s, eEF2, Tbp or Rpl0 as normalization control. Primer 
sequences are listed in SI Table 1. 
Immunoblotting - Tissues were homogenized in RIPA buffer, and equal amounts of proteins 
were separated on SDS-PAGE under reducing conditions, and transferred to a nitrocellulose 
membrane (Whatman). Proteins of interest were detected using the following antibodies: 
OXCT1 (ab105320; Abcam), ACAT1 (HPA004428; Sigma), eEF2 (2332; Cell signaling), 
Polyclonal Swine Anti-Rabbit Immunoglobulins/HRP (P0399, Dako). Densitometric analysis 
of immunoblots was performed on 6 individual samples using Image-J software, and a 
representative selection from this group is presented in each figure. 
Cell culture - C2C12 myoblasts were grown to confluence in Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 10% fetal calf serum and 1% penicillin/streptomycin (P/S). 
Cells were differentiated for 4 days in DMEM containing 2% horse serum and 1% P/S. All 
experiments were performed on differentiated C2C12 myotubes. Three independent 
experiments were performed in triplicates. PGC-1α was overexpressed by transduction with 
either GFP-PGC-1α or GFP (control) adenovirus. ERRα was knocked down using shERRα or 
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shLacZ (control) adenovirus. Cells were harvested 48 hours after infection. Myotubes were 
treated with either 10µM XCT-790 (Sigma) or 0.2% DMSO (vehicle) for 48 hours, or 30µm 
DY131 (Sigma) or 0.2% DMSO (vehicle) for 24 hours.  
Transcription factor binding sites prediction - Based on our previously published results 
from ChIP-Seq PGC-1α occupancy in muscle cells (12), a 10 kb long region located around 
the Oxct1 transcription start site (on chromosome 15 from 3’974’000 to 3’984’000 bp, mm9 
genome assembly) was scanned for ERRα transcription factor binding sites (TFBSs). In order 
to reduce false positive predictions, this 10 kb long region was aligned using the software T-
Coffee (13) to its orthologous regions from 6 different mammalian species (human, opossum, 
dog, rhesus macaque, horse and cow) and the resulting alignments were scanned with the 
motif search tool MotEvo (14) to predict TFBSs for the ERRα transcription factor (whose 
weight matrix was downloaded from the SwissRegulon database (15)). 
Statistical analysis - Data are presented as means ± SEM.  Unpaired student two-tailed t-test 
was used to determine differences between groups.  Significance was considered with p<0.05. 
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Results 
PGC-1α is a regulator of ketolytic gene transcription – Ketolytic capacity is high in 
oxidative organs such as brain, kidney, heart and skeletal muscle (2). To investigate the role 
of PGC-1α in ketolytic gene transcription in these organs, we used mice with a global deletion 
of PGC-1α (gKO) (10). Ablation of PGC-1α led to reduced transcript levels of ketolytic genes 
(e.g. Bdh1, Oxct1 and Acat1) in brain, kidney, heart and skeletal muscle (Fig. 1A). Since, 
skeletal muscle is an important tissue for maintenance of systemic KB homeostasis (2), we 
chose to investigate the role of skeletal muscle PGC-1α in systemic KB homeostasis. To this 
end, we used mice with a skeletal muscle-specific deletion of PGC-1α (mKO) (16). Similar to 
gKO mice (Fig. 1A), PGC-1α mKO mice displayed reduced transcription of ketolytic genes in 
both soleus (Fig. 1B) and gastrocnemius (Fig. 1C) muscles. We also detected reduced protein 
levels of OXCT1 and ACAT1 in gastrocnemius muscle (Fig. 1D). However, ketolytic gene 
transcription was similar in heart and kidney of mKO and control mice (SI Fig. 1A and B). In 
line with previous findings (17, 18), loss of PGC-1α led to a reduced transcription of genes 
involved in skeletal muscle lactate and KB uptake (Mct1) and TCA cycle genes (Cs, Aco2, 
Idh3a) important for mitochondrial oxidation of KBs (Fig. 1E). No difference could be seen 
for transcription of genes involved in non-oxidative KB metabolism (Aacs, Acat2) (Fig.1 E). 
Thus, PGC-1α regulates a broad transcriptional program in muscle necessary for KB uptake 
and mitochondrial KB oxidation. To test whether ablation of PGC-1α affects ketolytic 
capacity, we injected mice with βOHB and measured its clearance from the blood. Supporting 
a physiological relevance of the reduced ketolytic gene transcription in muscle, PGC-1α mKO 
mice showed an impaired βOHB excursion rate (Fig. 1F). Thus, PGC-1α mKO mice display 
reduced ketolytic gene transcription in muscle and ketolytic insufficiency. 
PGC-1α mKO mice exhibit hyperketonemia in response to fasting and ketogenic diet-
feeding – We next investigated whether loss of PGC-1α in muscle impacts systemic 
adaptation to physiological ketogenic stimuli, e.g. fasting and ketogenic diet feeding. PGC-1α 
mKO displayed a significant hyperketonemia compared to control mice after 24 hours of food 
withdrawal, in regard to both βOHB (Fig. 2A) and AcAc (Fig. 2B). These findings support 
the hypothesis of a ketolytic insufficient phenotype in mice lacking a functional PGC-1α gene 
in muscle. Intriguingly, this hyperketonemic phenotype was also observed in PGC-1α mKO 
mice after three weeks of low-carbohydrate ketogenic diet (LCKD) feeding (Fig. 2C). We 
also examined the ketogenic response in liver during fasting and LCKD feeding. In contrast to 
ketolytic gene transcription in muscle, control and PGC-1α mKO mice showed a similar 
induction of β-oxidation- and ketogenic gene programs in liver in response to both fasting 
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(Fig. 2D) and LCKD feeding (Fig. 2E). These findings indicate that the hyperketonemic 
phenotype of PGC-1α mKO mice is not due to alterations in the hepatic ketogenic response to 
either fasting or LCKD feeding. 
PGC-1α is necessary for the improved systemic ketolytic capacity with exercise training – 
Since PGC-1α mKO mice displayed hyperketonemia during fasting and LCKD feeding, we 
investigated whether this also occurs in response to other ketogenic stimuli, e.g. cold exposure 
and exercise. In line with our earlier findings (Fig. 2A-C), PGC-1α mKO mice developed 
hyperketonemia compared to control mice during cold exposure (Fig. 3A) and after an acute 
exercise bout (Fig. 3B). These data imply that muscle PGC-1α is important for systemic KB 
homeostasis, regardless of the ketogenic stimulus. Interestingly, exacerbated post-exercise 
ketosis is associated with an untrained phenotype in both rodents and humans, and can be 
ameliorated with exercise training (19, 20). Skeletal muscle PGC-1α could therefore be 
important for the adaptation of systemic ketolytic capacity with exercise training. To test this 
hypothesis, control and PGC-1α mKO mice had free access to running wheels for 8 weeks 
(trained group), while sedentary mice were kept in identical cages without running wheels. 
We first investigated the transcriptional profile in skeletal muscle from trained and sedentary 
mice. In line with previous reports (21), we observed a PGC-1α dependent induction of genes 
involved in oxidative phosphorylation (Uqcrc2, Sdhb, Ndufb8) and TCA-cycle (Aco2, Idh3a) 
in muscle from trained compared to sedentary mice (Fig. 3C). Interestingly, also ketolytic 
gene (Bdh1, Oxct1 and Acat1) transcription was significantly induced in muscle from trained 
compared to sedentary control mice, and this induction was blunted in trained PGC-1α mKO 
mice compared to control mice (Fig. 3D). To test whether the altered transcriptional profiles 
in muscle from control and PGC-1α mKO mice would affect systemic ketolytic capacity we 
injected mice with βOHB and measured its clearance from the blood. Importantly, while 
ketolytic capacity was improved in trained control mice, as indicated by the enhanced βOHB 
excursion rate (Fig. 3E), PGC-1α mKO mice displayed no improvement in ketolytic capacity 
with exercise (Fig. 3F). Thus, skeletal muscle PGC-1α is important for transcriptional 
induction of ketolytic genes in muscle and for improvement of systemic ketolytic capacity in 
trained mice. 
Elevation of PGC-1α levels in skeletal muscle improves systemic ketolytic capacity and 
ameliorates diabetic hyperketonemia – Since increased transcription of ketolytic genes in 
skeletal muscle correlated with an enhanced ketolytic capacity in trained mice, we were 
interested whether muscle-specific overexpression of PGC-1α in sedentary mice could 
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enhance the systemic ketolytic capacity. For this, we used mice with a skeletal muscle-
specific overexpression of PGC-1α (mTG mice) (9). PGC-1α mTG mice displayed an 
enhanced transcription of ketolytic genes (Bdh1, Oxct1 and Acat1) (Fig. 4A) and elevated 
protein levels of OXCT1 and ACAT1 in skeletal muscle (Fig. 4B). We also detected a minor 
overexpression of PGC-1α in heart of PGC-1α mTG mice (SI Fig. 1C). However, this was 
only associated with an induction of Bdh1 transcription, and did not further affect transcript 
levels of Acat1 or Oxct1 (SI Fig. 1C). In kidney, no alterations in transcript levels of either 
PGC-1α or ketolytic genes were observed in PGC-1α mTG mice (SI Fig. 1D). In skeletal 
muscle, PGC-1α mTG mice displayed increased transcript levels of genes involved in lactate 
and KB uptake (Mct1) and TCA cycle genes (Cs, Aco2, Idh3a) important for mitochondrial 
oxidation of KBs (Fig. 4C). While Aacs mRNA levels were unaltered in muscle from PGC-1α 
mTG mice, Acat2 transcription showed a small but significant induction (Fig. 4C). Thus, 
PGC-1α overexpression in muscle exerts only a minor transcriptional effect on genes involved 
in non-oxidative KB metabolism. Moreover, in line with the induction of a ketolytic gene 
program in muscle, PGC-1α mTG mice showed an enhanced βOHB excursion rate after 
βOHB injection (Fig. 4D), and thus an enhanced systemic ketolytic capacity. Importantly, in 
response to physiological ketogenic stimuli, such as fasting (Fig. 4E and F), LCKD feeding 
(Fig.4G) and exercise (Fig. 4H), mTG mice exhibited significantly reduced KB levels 
compared to control mice. Finally, in analogy with our findings in PGC-1α mKO mice (Fig. 
2D and E), mTG mice displayed a similar induction of β-oxidation- and ketogenic gene 
programs in liver in response to LCKD feeding (SI Fig. 1E) compared to control mice. Thus, 
elevation of PGC-1α levels increases expression of ketolytic enzymes in skeletal muscle and 
is sufficient to enhance the systemic ketolytic capacity in mice without altering the hepatic 
ketogenic response.  
Since elevation of PGC-1α levels in skeletal muscle led to reduced circulating KB 
levels, we hypothesized that activation of muscle PGC-1α could reduce diabetic 
hyperketonemia, which is a common and often fatal complication in type 1 diabetic patients 
(5). To assess whether elevated levels of PGC-1α in skeletal muscle reduced circulating KB 
levels during diabetes, we induced type 1 diabetes by injecting streptozotocin (STZ) (22) in 
both control and mTG mice. STZ-injected mice developed hallmark signs of type 1 diabetes, 
such as hyperglycemia (Fig. 5A), insulinopenia (Fig. 5B), elevated levels of free fatty acids in 
blood (Fig. 5C) and hyperketonemia (Fig. 5D). Importantly, while glucose, insulin and free 
fatty acid levels in blood were comparable between control and PGC-1α mTG mice, 
overexpression of PGC-1α in skeletal muscle efficiently reduced circulating βOHB levels in 
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diabetic mice (Fig. 5D). Furthermore, the reduced ketonemia in PGC-1α mTG mice could not 
be attributed to an impaired induction of β-oxidation- and ketogenic gene programs in liver of 
diabetic mice (Fig. 5E). Thus, without affecting the underlying insulin deficiency caused by 
the STZ injection, overexpression of PGC-1α in skeletal muscle can ameliorate 
hyperketonemia in type 1 diabetic mice. 
PGC-1α regulates ketolytic gene transcription through ERRα – Next, we aimed to identify 
the transcriptional partner of PGC-1α involved in the regulation of ketolytic gene 
transcription. Through overexpression of PGC-1α in C2C12 myotubes, we could confirm that 
elevated PGC-1α levels results in induction of ketolytic gene transcription (Bdh1, Oxct1 and 
Acat1) (Fig. 6A). Overexpression of PGC-1α also led to a concomitant increase in ERRα 
transcription in C2C12 myotubes (Fig. 6A). Since ERRα is a known transcriptional partner of 
PGC-1α in the regulation of mitochondrial and metabolic gene programs (23), we 
hypothesized that ERRα is also involved in the regulation of ketolytic gene transcription. To 
investigate the basal role of ERRα in ketolytic gene transcription, we performed a knockdown 
of ERRα in C2C12 myotubes using shERRα adenovirus. Knockdown of ERRα reduced 
transcript levels of both Oxct1 and Acat1, while Bdh1 transcription was unaffected (Fig. 6B). 
In contrast, activation of ERRβ and ERRγ with the dual ERRβ/γ agonist DY131 did not affect 
ketolytic gene transcription, while transcript levels of ERRγ and of the known ERR target 
gene pyruvate dehydrogenase kinase isozyme 4 (Pdk4) (24) were increased (Fig. 6C). Hence, 
activation of ketolytic gene transcription is specific for the ERRα-isoform. To substantiate the 
role of ERRα as a transcriptional partner of PGC-1α in the regulation of ketolytic gene 
transcription, we knocked down ERRα using shERRα adenovirus and concomitantly 
overexpressed PGC-1α (SI Fig. 1F), or in a second setup, overexpressed PGC-1α in C2C12 
myotubes in the presence of the inverse ERRα-agonist XCT790 (25) (Fig. 6D). In both setups, 
knockdown or inhibition of ERRα abrogated the induction of several shared PGC-1α/ERRα 
target genes such as ERRα and Idh3a (SI Fig. 1F and Fig. 6D). Importantly, inhibition of 
ERRα blocked the induction of ketolytic genes (Bdh1, Oxct1, Acat1) elicited by PGC-1α 
overexpression (SI Fig. 1F and Fig. 6D), indicating that ERRα is important for the induction 
of ketolytic gene transcription by PGC-1α in muscle cells. Finally, to elucidate whether Bdh1, 
Oxct1 and Acat1 are directly regulated by interaction of PGC-1α and ERRα, we investigated 
data-sets on genome-wide occupancy of PGC-1α (12) and ERRα (unpublished data). 
Surprisingly, we could not detect any peaks for either PGC-1α or ERRα in the vicinity of the 
Acat1 and Bdh1 genes (data not shown), indicating that these genes are most likely indirectly 
regulated by PGC-1α and ERRα in skeletal muscle. On the other hand, we found overlapping 
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peaks for PGC-1α and ERRα within the Oxct1 gene (Fig. 6E), indicating that these 
transcriptional regulators are bound to the DNA at the same site within the Oxct1 gene. 
Moreover, by using MotEvo (14) to predict transcription factor binding sites, a putative 
response element for ERRα was identified within the genomic region occupied by PGC-1α 
and ERRα in the Oxct1 gene (Fig. 6E). These findings indicate that PGC-1α and ERRα likely 
regulate Oxct1 transcription by directly binding to this gene. 
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Discussion 
KBs are vital metabolic substrates during states of reduced carbohydrate availability (1). 
Systemic KB levels are determined by the interplay of hepatic ketone body production and 
KB utilization in extra-hepatic organs. We now show that PGC-1α is a transcriptional 
regulator of ketolytic enzymes in several extra-hepatic organs, and that skeletal muscle PGC-
1α determines systemic KB homeostasis in contexts of elevated KB levels, including fasting, 
cold exposure and exercise (Fig. 7). It is important to note that the overall effect of muscle 
PGC-1α on systemic KB homeostasis is likely due to two interrelated factors: 1) The role of 
PGC-1α in transcription of KB transporters and ketolytic enzymes in muscle, and 2) the 
established role of PGC-1α for the transcription of related mitochondrial metabolic pathways, 
such as TCA cycle and oxidative phosphorylation (8). PGC-1α thus regulates transcription of 
several interconnected metabolic pathways in muscle necessary for complete oxidation of 
KBs. Importantly, we could show that elevated PGC-1α levels in skeletal muscle reduces 
pathophysiological hyperketonemia in mice. Aberrant regulation of KB levels in type 1 
diabetic patients can lead to diabetic ketoacidosis, which is a potentially fatal complication 
arising from exacerbated lipolysis and elevated ketogenesis associated with diabetic 
insulinopenia. Thus, patients suffering from acute diabetic ketoacidosis are primarily treated 
with insulin to reverse the insulin-deficient state (5). In analogy with the KB-lowering effect 
of exercise in diabetic rats (26), we now report that elevation of muscle PGC-1α levels 
reduces hyperketonemia in a mouse model of type 1 diabetes. These findings imply that 
chronic elevation of PGC-1α levels in muscle could help reduce the intensity of 
hyperketonemic bouts in type 1 diabetic patients. Here, it is important to point out that 
diabetic ketoacidosis is an acute and life-threatening condition, which requires immediate 
treatment. Thus, acute activation of PGC-1α in muscle would not be a feasible therapeutic 
strategy in this case. However, by chronically increasing the basal levels of PGC-1α in muscle 
through regular exercise training (27), and consequently increasing the ketolytic capacity of 
muscle, this would be useful as a preventive measure to reduce the incidence and intensity of 
hyperketonemic bouts in diabetic patients. In this case, it is also important to distinguish 
between the beneficial effects of continuous exercise training, compared to the acute 
metabolic alterations associated with exercise, which could precipitate or even exacerbate a 
diabetic hyperketonemic bout (28). 
Exercise can modulate the systemic response to ketosis, which is evident by the 
enhanced KB tolerance (29) and resistance to post-exercise ketosis in trained humans (20) and 
rodents (19). Resistance to post-exercise ketosis with exercise has been attributed to a sparing 
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of liver glycogen content during exercise (19). However, reduction in post-exercise ketosis 
could also be mediated by adaptations of cardiac and skeletal muscle, two main consumers of 
KBs. In line with this, endurance training in rats enhances KB uptake into muscle and 
increases the levels of ketolytic enzymes in muscle (30, 31). We now demonstrate that muscle 
PGC-1α plays an important role in the adaptation of ketolytic capacity with long-term 
exercise training. These findings underline the importance of skeletal muscle in the regulation 
of KB homeostasis, and imply PGC-1α as a major regulator of this process. Additionally, we 
show that transcription of ketolytic genes is either directly or indirectly controlled by the 
interaction of PGC-1α with ERRα. It is well established that ERRα and PGC-1α stimulate the 
transcription of genes involved in several metabolic processes in skeletal muscle, such as 
oxidative phosphorylation, lactate metabolism and fatty acid β-oxidation (18, 25, 32). Thus, 
the functional interaction between PGC-1α and ERRα in the regulation of ketolysis most 
likely allows an integrated coordination of different metabolic pathways in skeletal muscle 
and other organs. It would thus be interesting in future studies to evaluate the role of PGC-1α 
and ERRα in the regulation of KB homeostasis in other ketolytic organs, such as the brain. 
This is of particular importance in the context of long-term fasting, where KB oxidation is 
essential for maintenance of energy homeostasis in neurons (1).  
In summary, we have identified PGC-1α as a transcriptional regulator of KB oxidation 
in skeletal muscle (Fig. 7). Moreover, we show that muscle PGC-1α plays an important role in 
the regulation of systemic KB levels, both in physiological contexts of KB utilization, but also 
in pathological settings such as diabetic ketoacidosis. Hence, activation of PGC-1α in skeletal 
muscle could have an important therapeutic impact by reducing the extent of hyperketonemic 
bouts in disease states characterized by pathological elevation of KB levels, e.g. type 1 
diabetes. However, until pharmacological means to therapeutically elevate PGC-1α in skeletal 
muscle become available, regular exercise training is the safest and most efficient way to 
increase the baseline ketolytic capacity in this organ and thus affect systemic KB homeostasis. 
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Figure legends 
Figure 1 - PGC-1α mKO mice display reduced expression of ketolytic enzymes in 
skeletal muscle 
Experiments performed with control and (A) PGC-1α gKO mice or (B-F) PGC-1α mKO. (A) 
Gene expression in brain, kidney, heart and gastrocnemius normalized to 18s (n=5/group). (B-
C) Gene expression in (B) soleus and (C) gastrocnemius muscle normalized to 18s 
(n=8/group). (D) Representative immunoblots of OXCT1, ACAT1 and eEF2 in 
gastrocnemius. Graph shows quantification of band intensities of OXCT1 and ACAT1 
relative to eEF2 (n=6/group). (E) Gene expression in gastrocnemius normalized to 18s 
(n=8/group). (F) Blood βOHB levels after an intraperitoneal βOHB-injection (n=6/group). 
Error bars represent mean ±SEM. Significant differences (p-value<0.05) between genotypes 
are indicated by an asterisk (*) and between experimental conditions by a number-sign (#). 
Figure 2 – Skeletal muscle PGC-1α modulates systemic ketone body homeostasis 
Experiments performed with control and PGC-1α mKO mice. (A-B) Blood β-hydroxybutyrate 
(βOHB) (A) or plasma acetoacetate (AcAc) (B) levels in fed or 24-hour fasted mice (n=7-
8/group). (C) βOHB levels in mice fed either chow or a LCKD for 3 weeks (n=7-13/group). 
(D) Liver gene expression from ad libitum fed or 24 hour fasted mice, normalized to 18s 
(n=6-9/group). (E) Liver gene expression of mice fed a chow diet or LCKD diet for 3 weeks, 
normalized to 18s (n=7-8/group). Error bars represent mean ±SEM. Significant differences (p-
value<0.05) between genotypes are indicated by an asterisk (*) and between experimental 
conditions by a number-sign (#). 
Figure 3 - Skeletal muscle PGC-1α is necessary for improved systemic ketolytic capacity 
with exercise training 
Experiments performed with control and PGC-1α mKO mice. (A) Blood βOHB levels of mice 
at room temperature (RT) or 4°C (Cold exp.) (n=5-8/group). (B) βOHB levels pre-exercise 
and at 0/30/180 minutes post-exercise (n=5/group). (C-D) Gastrocnemius gene expression 
normalized to 18s (n=6-8/group). (E-F) Blood βOHB levels after an intraperitoneal βOHB-
injection in sedentary or trained (E) control and (F) PGC-1α mKO mice (n=6/group). Error 
bars represent mean ±SEM. Significant differences (p-value<0.05) between genotypes are 
indicated by an asterisk (*) and between experimental conditions by a number-sign (#). 
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Figure 4 - Muscle-specific overexpression of PGC-1α increases systemic ketolytic 
capacity and ameliorates diabetic hyperketonemia 
Experiments performed with control and PGC-1α mTG mice. (A) Gene expression in 
gastrocnemius muscle normalized to 18s (n=8/group). (B) Representative immunoblots of 
OXCT1, ACAT1 and eEF2 in gastrocnemius muscle. Bar graph shows quantification of band 
intensities of OXCT1 and ACAT1 relative to eEF2 (n=6/group). (C) Gene expression in 
gastrocnemius muscle normalized to 18s (n=8/group). (D) Blood βOHB levels after an 
intraperitoneal βOHB-injection (n=10-11/group). (E-F) Blood βOHB (E) or plasma AcAc (F) 
levels in fed or 24-hour fasted mice (n=7-10/group). (G) βOHB levels in mice fed a chow or 
LCKD diet for 3 weeks (n=6-8/group). (H) βOHB levels pre-exercise and at 0/30/180 minutes 
post-exercise (n=6/group). Error bars represent mean ±SEM. Significant differences (p-
value<0.05) between genotypes are indicated by an asterisk (*) and between experimental 
conditions by a number-sign (#). 
Figure 5 - Muscle-specific overexpression of PGC-1α ameliorates hyperketonemia in 
diabetic mice 
Experiments performed with control and PGC-1α mTG mice. (A-D) Blood glucose (A), 
plasma insulin (B), plasma free fatty acids (C) and blood βOHB levels (D) in mice 3 days 
after injection with either citrate buffer (CB) or 150 mg/kg streptozotocin (STZ) (n=7-
17/group). (E) Liver gene expression of mice injected with either CB or STZ, normalized to 
Tbp (n=6-9/group). Error bars represent mean ±SEM. Significant differences (p-value<0.05) 
between genotypes are indicated by an asterisk (*) and between experimental conditions by a 
number-sign (#). 
Figure 6 - PGC-1α regulates ketolytic gene transcription through co-activation of ERRα 
(A) C2C12 myotubes transduced with GFP or GFP-PGC-1α adenovirus. Gene expression 
normalized to 18s. (B) ERRα was knocked down in C2C12 myotubes using shERRα 
adenovirus or shLacZ (control). Gene expression normalized to RPL0. (C) C2C12 myotubes 
treated for 24 hours with 30μM DY131 or 0.2% DMSO (VEH). Gene expression normalized 
to eEF2. (D) C2C12 myotubes transduced with GFP or GFP-PGC-1α adenovirus, and co-
treated with 0.2% DMSO (VEH) or 10μM XCT-790 (XCT). Gene expression normalized to 
18s. (E) ChIP-Seq peaks, depicted as read profiles for PGC-1α (dark blue) and ERRα (light 
blue).  The most prominent peak is located ~7kb downstream of the Oxct1 transcription start 
site (TSS) and within the first intron. The predicted binding site for ERRα is represented by a 
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yellow circle and its genomic position is referred to the Oxct1 TSS. The bottom panel 
represents an enlargement of the above relevant regions. Error bars represent mean ±SEM. 
Significant differences (p-value<0.05) between treated and control condition are indicated by 
an asterisk (*) and between experimental conditions by a number-sign (#). 
Figure 7 - PGC-1α is an important regulator of skeletal muscle ketone body oxidation. 
(a) PGC-1α/ERRα directly regulates transcription of Oxct1, while Acat1 and Bdh1 are 
indirectly regulated (b) Modulation of PGC-1α levels in skeletal muscle alters systemic 
ketone body levels in response to either fasting, ketogenic diet feeding or exercise (c) PGC-1α 
levels in skeletal muscle modulate expression of proteins important for mitochondrial KB 
uptake and oxidation, such as Mct1, Bdh1, Oxct1, Acat1 and components of the TCA-cycle. 
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Supplemental data Figure 1 
(A‐B) Gene expression in heart (A) and kidney (B) from PGC‐1α mKO mice, normalized to 18s 
(n=6/group).  (C‐D) Gene  expression  in  heart  (C)  and  kidney  (D)  from  PGC‐1α mTG mice, 
normalized to 18s  (n=7/group).  (E) Gene expression  in  liver  from control and PGC‐1α mTG 
mice,  normalized  to  18s  (n=6/group).  (F)  C2C12  myotubes  transduced  with  adenovirus 
expressing  either GFP  or  shERRα. GFP  or  shLacZ were  used  as  controls. Gene  expression 
normalized  to Tbp. Error bars  represent mean ±SEM. Significant differences  (p‐value<0.05) 
between genotypes are indicated by an asterisk (*) and between experimental conditions by 
a number‐sign (#). 
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Table S1. qPCR Primer sequences 
 
Target 
gene 
Forward primer  Reverse primer 
Aacs 
Acat1 
Acat2 
Aco2 
Bdh1 
Cd36 
Cpt1b 
Cs 
Errα 
Errβ 
Errγ 
Hmgcl 
Hmgcs2 
Idh3a 
Lcad 
Mct1 
Mct2 
Mct4 
Ndufb8 
Oxct1 
Pdk4 
PGC‐1α 
Sdhb 
Uqcrc2 
 
 
AAGGACATGAAGCCAGTGGAAA 
GTGAAGGAAGTCTACATGGGCA 
ATTCAAAACATGGGGATTCGGC 
ACATTGTCCGTAAACGGTTGAA 
TTTGCTGGCTGTTTGATGAAGG 
GGCAAAGAACAGCAGCAAAAT 
ATCATGTATCGCCGCAAACT 
CCCAGGATACGGTCATGCA 
CGGTGTGGCATCCTGTGA 
CAGATCGGGAGCTTGTGTTC 
GGAAGAATTCGTCACCCTCA 
CCAGCTTTGTTTCTCCCAAGTG 
CCACAAGGTGAACTTCTCTCCA 
GCTGGTGGTGTTCAGACAGTAA 
CCAGCTAATGCCTTACTTGGAGA 
TGCAACGACCAGTGAAGTATCA 
AGGAAACCCCCAAAGCAAGAG 
AGAGCACTTAAAGTCGCCCCC 
CAAGAAGTATAACATGCGAGTGGAA 
CCCATACCCACTGAAAGACGAA 
AAAATTTCCAGGCCAACCAA 
AGCCGTGACCACTGACAACGAG 
TGACGTCAGGAGCCAAAATGG 
CCCATCTTGCTTTGCTGTCTG 
ACTCGTAACTCTGGGCTTTCAG 
TGTGGTGCATGGAGTGGAAATA 
TCAATGGGAAACCGAGAGACAG 
TATGTCTTTCCCCGCTCGATCT 
TTGAGCTGGATGGTTCTCAGTC 
TGGCTAGATAACGAACTCTGTATGTGT 
CCATCTGGTAGGAGCACATGG 
GCAAACTCTCGCTGACAGGAA 
CTCCCCTGGATGGTCCTCTT 
TGGTCCCCAAGTGTCAGACT 
TTCTGCACAGCTTCCACATC 
GATGCCGGGAAACTTCTGAATG 
TGCATCTCATCCACTCGTTCAA 
CACTGAATAGGTGCTTTGGCAG 
GCAATTAAGAGCCTTTCCTGTGG 
ACAACCACCAGCGATCATTACT 
GGAAGGCTCTGATGGCATTTC 
GGGCTGCTTTCACCTGTTACC 
CCATACCCCATGCCATCATC 
CTGGAGAAGAAAGAGGCTCCTG 
CGAAGAGCATGTGGTGAAGGT 
GCTGCATGGTTCTGAGTGCTAAG 
CCTCGACAGGCCTGAAACTG 
AATAAAATCTCGAGAAGGACCCG 
 
 
